• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Understanding ALS/MND Research

Research is how new treatments, better care, and answers about the causes of ALS/MND are found. It ranges from work in a laboratory to studies that follow people over many years. People living with ALS/MND, caregivers, and families take part at every stage.

This page explains the main types of research, how a treatment moves from the laboratory to approval, and what taking part in a clinical trial involves. It also links to Alliance pages that go into more detail and to research organizations you can follow.

On this page

Types of research  │  From laboratory to approval  │  Learn more  │  Research organizations

Types of research

Different types of research answer different questions. Most progress depends on several of them working together.

Laboratory and pre-clinical research

Scientists study cells, tissue, and animal models to understand how ALS/MND develops and to test ideas for treatments before they are tried in people. This includes genetics and genomics, which look for genes linked to the disease, and biomarker research. Biomarkers are measurable signs, found for example in blood or spinal fluid, that may show whether a disease is present, how fast it is progressing, or whether a treatment is working.

Epidemiology

Epidemiology studies how many people are affected by ALS/MND, who they are, and why patterns differ between populations and regions.

Clinical trials

Clinical trials are research studies with people. They can test a treatment (interventional trials) or follow people over time without giving a treatment (observational studies). Interventional trials look at safety, tolerability, and whether a treatment works.

Care and clinical management research

This research looks at how to deliver better care today. Examples include how multidisciplinary clinics are organized, and how assistive technology, rehabilitation, or social support can improve quality of life.

Social science research

Social science research asks people living with ALS/MND and caregivers about their experiences and priorities, so that research and care address what matters most to them.

How a treatment moves from the laboratory to approval

Before a new treatment can be approved, it goes through several steps. Regulatory agencies review the results, and each country decides for itself whether to approve a treatment.

  1. Pre-clinical research. A possible treatment is tested in the laboratory to see whether it is likely to be safe and effective.
  2. Phase 1. A small group of people receives the treatment. The main goals are to check safety and find a suitable dose.
  3. Phase 2. A larger group receives the treatment. Researchers look for early signs that it works and continue to monitor safety.
  4. Phase 3. A larger group is studied, usually comparing the treatment with a placebo or with standard care. A placebo is an inactive treatment used for comparison. Results from this phase are the main evidence regulators review.
  5. Regulatory review. The regulatory agency in each country reviews the evidence and decides whether to approve the treatment.

Some newer trials are called platform trials. They test several treatments at the same time within one trial structure, which can speed up the search for effective therapies.

Learn more on this website

Recommendations for Trial Sponsors
What the Alliance expects from sponsors after a trial ends.

Open Label Extension
Continued access to a study treatment after a trial.

Expanded Access

Unproven Treatments

Open Science

Improving Regulatory Pathways

Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research

Genetics

Drugs in development: SOD1 Therapies and Trials and C9orf72 Therapies and Trials

Resources on research

These Alliance members publish research updates and news.

ALS Canada Research Program

ALS Canada · English

ALS Canada funds fundamental and clinical research in Canada and brings the national ALS research community together to share ideas and collaborate.

Visit the ALS Canada Research Program →

ALS Therapy Development Institute

ALS Therapy Development Institute · United States · English

ALS TDI is a nonprofit biotech and drug discovery laboratory focused only on ALS.

Visit ALS TDI Research →

Les Turner ALS Center at Northwestern Medicine

Les Turner ALS Foundation · United States · English

The Les Turner ALS Foundation supports research at Northwestern University Feinberg School of Medicine, including studies of genetic causes of ALS and of how motor neurons degenerate.

Visit the Les Turner ALS Center →

European Network to Cure ALS (ENCALS)

ENCALS · English

ENCALS is a network of ALS centres in Europe. It holds an annual scientific meeting, gives awards to early-career researchers, and publishes a directory of ALS centres.

Visit ENCALS →

Project MinE

Project MinE consortium · English

Project MinE is an international research consortium that analyzes whole genome sequencing data to find genetic variants that contribute to ALS. It is building a publicly accessible repository of this data.

Visit Project MinE →

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Eddy Lefrancois, Canada

    Eddy Lefrancois, Canada

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Ali Var, Turkey

    Ali Var, Turkey

  • Jeff Sutherland, Canada

    Jeff Sutherland, Canada
    jspic

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Susan Keldani, USA

    Susan Keldani, USA

  • Mary Thomas, Australia

    Mary Thomas, Australia

  • David Solomon, UK

    David Solomon, UK

  • Len Johnrose, England

    Len Johnrose, England

  • Steve Gallagher, Canada

    Steve Gallagher, Canada
    Picture1

  • Susan Anderson, USA

    Susan Anderson, USA

  • Timmy, Belgium

    Timmy, Belgium

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Lachlan Terry, Australia

    Lachlan Terry, Australia

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Mike Rannie, Canada

    Mike Rannie, Canada

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Karl Hughes, Ireland

    Karl Hughes, Ireland

  • Cliff Marshman, USA

    Cliff Marshman, USA
    CliffMarshman

  • Claudia Cominetti, Italy

    Claudia Cominetti, Italy

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Maria Lucia Wood Saldanha, Brazil

    Maria Lucia Wood Saldanha, Brazil

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Lee Millard, England

    Lee Millard, England

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Richard Clark, New Zealand

    Richard Clark, New Zealand

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • Sébastien Batiot, France

    Sébastien Batiot, France

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Monica Soriano, Argentina

    Monica Soriano, Argentina

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Ian Gale, Australia

    Ian Gale, Australia

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login